Immunovant (IMVT) EBT (2018 - 2026)
Immunovant's (IMVT) quarterly EBT came in at -$150.7 million in Q1 2026, down 42.35% YoY from -$261.4 million in Q1 2025, and down 38.15% on a QoQ basis from -$109.1 million in Q4 2025.
Immunovant (IMVT) EBT (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of EBT data on file, last reported at -$150.7 million in Q1 2026.
- Quarterly EBT fell 42.35% year-over-year to -$150.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$505.4 million (down 22.39% YoY) and the FY2026 annual result came in at -$505.4 million, down 22.39% from the prior year.
- EBT fell to -$150.7 million in Q1 2026, from -$109.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$40.0 million in Q2 2022 to a low of -$150.7 million in Q1 2026.
- A 5-year average of -$84.4 million and a median of -$75.1 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT advanced 18.0% — and 2024, when it slumped 115.37%.
- Tracing IMVT's EBT over 5 years: stood at -$62.8 million in 2022, then rose by 18.0% to -$51.5 million in 2023, then tumbled by 115.37% to -$111.0 million in 2024, then rose by 1.7% to -$109.1 million in 2025, then plunged by 38.15% to -$150.7 million in 2026.
- The last three EBT figures came in at -$150.7 million (Q1 2026), -$109.1 million (Q4 2025), and -$125.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | -153.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -153.22 Mn |
| Mar 31, 2026 | -150.70 Mn |
| Dec 31, 2025 | -109.08 Mn |
| Sep 30, 2025 | -125.91 Mn |
| Jun 30, 2025 | -119.70 Mn |
| Mar 31, 2025 | -105.87 Mn |
| Dec 31, 2024 | -110.97 Mn |
| Sep 30, 2024 | -109.04 Mn |
| Jun 30, 2024 | -87.07 Mn |
| Mar 31, 2024 | -75.09 Mn |
| Dec 31, 2023 | -51.53 Mn |
| Sep 30, 2023 | -58.21 Mn |
| Jun 30, 2023 | -73.95 Mn |
| Mar 31, 2023 | -60.42 Mn |
| Dec 31, 2022 | -62.84 Mn |
| Sep 30, 2022 | -47.67 Mn |
| Jun 30, 2022 | -40.02 Mn |
| Mar 31, 2022 | -47.18 Mn |
| Dec 31, 2021 | -41.39 Mn |
| Sep 30, 2021 | -37.73 Mn |